Lupin has received approval from China’s National Medical Products Administration for its Abbreviated New Drug Application for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals, a leader in China’s paediatric medicine market. This marks the company’s first product entry into China - a significant step in its global expansion.
Oseltamivir Phosphate for oral suspension, 6 mg/mL will be launched and commercialized to expand access, particularly for paediatric use. This expands the company’s global footprint and its commitment to delivering high-quality, affordable medicines to patients and children in need. Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL is indicated for treatment of influenza A and B in patients 2 weeks of age and older; and for prevention of influenza A and B in individuals 1 year of age and older.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1828.75 |
| Dr. Reddys Lab | 1265.90 |
| Cipla | 1358.10 |
| Zydus Lifesciences | 1077.20 |
| Lupin | 2329.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: